For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

AstraZeneca PLC ADR closed 14.46% short of its 52-week high of $87.68, which the company reached on August 30th.

AstraZeneca’s share price has fallen a lot from its September high, but this could mean a tremendous opportunity for me to ...

AstraZeneca PLC closed 17.61% short of its 52-week high of £133.88, which the company reached on September 3rd.

The most recent trading session ended with Astrazeneca (AZN) standing at $73.83, reflecting a +1.12% shift from the previouse ...

An AstraZeneca Plc affiliate suffered a greater than $180 million court loss Wednesday over its lackluster efforts to ...

Understand every aspect of the global economy – and know how to make your next move.

The thing that I worry about more than loss of exclusivity is this term that I introduced at the AACR meeting -- loss of relevancy" says Susan Galbraith, EVP of Oncology R&D at AstraZeneca.

Drugmaker AstraZeneca has agreed to pay $50.9 million to settle a class action lawsuit in U.S. court accusing the company of ...

AstraZeneca’s rare disease business, Alexion, has partnered with British health tech Pangaea Data to fund the startup’s ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...